Medapia

Entacapone, the active ingredient in Medapia, is a catechol-O-methyltransferase (COMT) inhibitor presented as an oral formulation for oral use. It is used as an adjunct to levodopa/carbidopa therapy in patients with Parkinson's disease to extend levodopa's duration of action and reduce motor fluctuations.

GNH USA supplies Medapia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Entacapone is employed in the Parkinson's disease treatment pathway as a COMT inhibitor that enhances levodopa therapy. - Parkinson's disease (adjunct to levodopa/carbidopa): prolongs levodopa half‑life and improves motor control. - Levodopa‑induced motor fluctuations: reduces OFF periods and stabilises symptom control. - Parkinson's disease patients on levodopa/carbidopa: increases on‑time without worsening dyskinesia.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools occurring shortly after dosing. - Abdominal pain: cramping or discomfort in the stomach area. - Urine discoloration: brownish tint that is harmless. - Dyskinesia: involuntary movements, often related to levodopa levels. - Headache: transient mild to moderate pain.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Neutropenia: marked reduction in white blood cells. - Hyperbilirubinemia: abnormal increase in bilirubin levels.

Entacapone should be used with careful clinical monitoring. - Liver monitoring: assess hepatic function before initiation and periodically during therapy. - Dyskinesia assessment: watch for increased involuntary movements, especially when levodopa dose is high. - Renal function: evaluate kidney status in patients with impaired clearance. - Concomitant MAO‑B inhibitors: avoid or use with caution due to potential hypertensive effects. - Elderly patients: start at lower doses and monitor for adverse reactions. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Entacapone may interact with several drug classes. Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis when combined. - Other COMT inhibitors: additive inhibition may increase levodopa exposure. Moderate Interactions (Monitor Closely): - Anticholinergic agents: may enhance anticholinergic side effects. - NSAIDs: potential for increased gastrointestinal irritation. - Antihypertensive drugs: possible additive blood pressure lowering effect.